Global Spinal Muscular Atrophy Medicine Supply, Demand and Key Producers, 2026-2032
The global Spinal Muscular Atrophy Medicine market size is expected to reach $ 15557 million by 2032, rising at a market growth of 17.4% CAGR during the forecast period (2026-2032).
Spinal Muscular Atrophy Medicine refers to a general category of pharmaceutical products used for the treatment of spinal muscular atrophy, a rare inherited neuromuscular disease. Spinal muscular atrophy is an autosomal recessive disorder primarily caused by homozygous deletion or mutation of the survival motor neuron 1 gene, leading to deficiency of survival motor neuron protein function, which in turn triggers degeneration of spinal cord anterior horn motor neurons and results in progressive muscle weakness and atrophy in patients. The severity of the disease is inversely correlated with survival motor neuron 2 gene copy number, with fewer copies leading to more severe disease. From an industrial attribute perspective, Spinal Muscular Atrophy Medicine sits at the intersection of gene therapy, antisense oligonucleotide technology, small molecule drug development, and rare disease treatment. Three disease modifying therapies have been approved globally, each increasing functional survival motor neuron protein levels through different mechanisms. The core value of these drugs lies in fundamentally changing the natural history of spinal muscular atrophy, particularly enabling near normal motor development in children treated during the presymptomatic stage.
Market Development Opportunities and Main Drivers
The global expansion of newborn screening programs has promoted early diagnosis of spinal muscular atrophy, with identification of the presymptomatic treatment window becoming a key factor in improving prognosis. The recommendation statement issued by the US Preventive Services Task Force provides policy basis for newborn screening. Next generation gene therapy vectors are improving delivery efficiency and targeting specificity, while the convenience of oral small molecule drugs has significantly enhanced patient adherence to long term treatment. Biogen’s nusinersen, as the first approved spinal muscular atrophy medicine, has received regulatory approval in multiple countries and regions. Novartis’s onasemnogene abeparvovec, as a one time intravenous gene therapy, represents a curative treatment direction. Roche’s risdiplam, as an orally administered small molecule drug, has expanded treatment options.
Market Challenges and Risks
The one time treatment cost of gene therapy stands at the peak of the innovative drug pricing system, posing pressure on healthcare payment capacity. Some patients cannot receive gene therapy due to pre existing neutralizing antibodies against adeno associated virus, limiting the eligible population. Long term safety and durability data are still being accumulated, particularly regarding the lifelong impact of gene therapy in pediatric patients requiring extended follow up confirmation. The large scale manufacturing capacity and quality control requirements for viral vectors are demanding, with capacity expansion facing technical bottlenecks. Marketed products face competitive pressure from subsequent generation therapies, with next generation drugs under clinical development.
Downstream Demand Trends
Patients with infantile onset type 1 spinal muscular atrophy show the most urgent need for rapid acting gene therapy, with presymptomatic treatment representing the optimal intervention window. Patients with type 2 and type 3 spinal muscular atrophy show growing demand for long term oral maintenance therapy, with convenience becoming an important consideration. The adult onset type 4 patient population is receiving increased attention for their need to delay disease progression. The expansion of carrier screening and prenatal diagnosis has spurred discussions on preventive interventions. Notably, combination therapy strategies are being explored clinically, combining gene therapy with oral small molecule drugs to pursue additive efficacy.
Regional Trends
The North American market, with its comprehensive newborn screening systems, strong healthcare coverage, and concentration of innovative companies, leads in the commercialization of Spinal Muscular Atrophy Medicines. The European market, influenced by public healthcare budget constraints, applies relatively strict cost effectiveness assessments for medicines, but patient registries and real world evidence accumulation are relatively mature. The Asia Pacific region, benefiting from accelerated review policies for rare disease drugs in countries including China and Japan, is seeing rapid improvement in patient access, with the National Medical Products Administration of China having included multiple Spinal Muscular Atrophy Medicines in its priority review channel.
This report studies the global Spinal Muscular Atrophy Medicine production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Spinal Muscular Atrophy Medicine and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Spinal Muscular Atrophy Medicine that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Spinal Muscular Atrophy Medicine total production and demand, 2021-2032, (K Dose)
Global Spinal Muscular Atrophy Medicine total production value, 2021-2032, (USD Million)
Global Spinal Muscular Atrophy Medicine production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Dose), (based on production site)
Global Spinal Muscular Atrophy Medicine consumption by region & country, CAGR, 2021-2032 & (K Dose)
U.S. VS China: Spinal Muscular Atrophy Medicine domestic production, consumption, key domestic manufacturers and share
Global Spinal Muscular Atrophy Medicine production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Dose)
Global Spinal Muscular Atrophy Medicine production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
Global Spinal Muscular Atrophy Medicine production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
This report profiles key players in the global Spinal Muscular Atrophy Medicine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Biogen, Novartis, Roche, Sanofi, Ionis Pharma, Genethon, Scholar Rock, AskBio, Pfizer, PTC Therapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Spinal Muscular Atrophy Medicine market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Dose) and average price (US$/Dose) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Spinal Muscular Atrophy Medicine Market, By Region:
1. How big is the global Spinal Muscular Atrophy Medicine market?
2. What is the demand of the global Spinal Muscular Atrophy Medicine market?
3. What is the year over year growth of the global Spinal Muscular Atrophy Medicine market?
4. What is the production and production value of the global Spinal Muscular Atrophy Medicine market?
5. Who are the key producers in the global Spinal Muscular Atrophy Medicine market?
6. What are the growth factors driving the market demand?
Spinal Muscular Atrophy Medicine refers to a general category of pharmaceutical products used for the treatment of spinal muscular atrophy, a rare inherited neuromuscular disease. Spinal muscular atrophy is an autosomal recessive disorder primarily caused by homozygous deletion or mutation of the survival motor neuron 1 gene, leading to deficiency of survival motor neuron protein function, which in turn triggers degeneration of spinal cord anterior horn motor neurons and results in progressive muscle weakness and atrophy in patients. The severity of the disease is inversely correlated with survival motor neuron 2 gene copy number, with fewer copies leading to more severe disease. From an industrial attribute perspective, Spinal Muscular Atrophy Medicine sits at the intersection of gene therapy, antisense oligonucleotide technology, small molecule drug development, and rare disease treatment. Three disease modifying therapies have been approved globally, each increasing functional survival motor neuron protein levels through different mechanisms. The core value of these drugs lies in fundamentally changing the natural history of spinal muscular atrophy, particularly enabling near normal motor development in children treated during the presymptomatic stage.
Market Development Opportunities and Main Drivers
The global expansion of newborn screening programs has promoted early diagnosis of spinal muscular atrophy, with identification of the presymptomatic treatment window becoming a key factor in improving prognosis. The recommendation statement issued by the US Preventive Services Task Force provides policy basis for newborn screening. Next generation gene therapy vectors are improving delivery efficiency and targeting specificity, while the convenience of oral small molecule drugs has significantly enhanced patient adherence to long term treatment. Biogen’s nusinersen, as the first approved spinal muscular atrophy medicine, has received regulatory approval in multiple countries and regions. Novartis’s onasemnogene abeparvovec, as a one time intravenous gene therapy, represents a curative treatment direction. Roche’s risdiplam, as an orally administered small molecule drug, has expanded treatment options.
Market Challenges and Risks
The one time treatment cost of gene therapy stands at the peak of the innovative drug pricing system, posing pressure on healthcare payment capacity. Some patients cannot receive gene therapy due to pre existing neutralizing antibodies against adeno associated virus, limiting the eligible population. Long term safety and durability data are still being accumulated, particularly regarding the lifelong impact of gene therapy in pediatric patients requiring extended follow up confirmation. The large scale manufacturing capacity and quality control requirements for viral vectors are demanding, with capacity expansion facing technical bottlenecks. Marketed products face competitive pressure from subsequent generation therapies, with next generation drugs under clinical development.
Downstream Demand Trends
Patients with infantile onset type 1 spinal muscular atrophy show the most urgent need for rapid acting gene therapy, with presymptomatic treatment representing the optimal intervention window. Patients with type 2 and type 3 spinal muscular atrophy show growing demand for long term oral maintenance therapy, with convenience becoming an important consideration. The adult onset type 4 patient population is receiving increased attention for their need to delay disease progression. The expansion of carrier screening and prenatal diagnosis has spurred discussions on preventive interventions. Notably, combination therapy strategies are being explored clinically, combining gene therapy with oral small molecule drugs to pursue additive efficacy.
Regional Trends
The North American market, with its comprehensive newborn screening systems, strong healthcare coverage, and concentration of innovative companies, leads in the commercialization of Spinal Muscular Atrophy Medicines. The European market, influenced by public healthcare budget constraints, applies relatively strict cost effectiveness assessments for medicines, but patient registries and real world evidence accumulation are relatively mature. The Asia Pacific region, benefiting from accelerated review policies for rare disease drugs in countries including China and Japan, is seeing rapid improvement in patient access, with the National Medical Products Administration of China having included multiple Spinal Muscular Atrophy Medicines in its priority review channel.
This report studies the global Spinal Muscular Atrophy Medicine production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Spinal Muscular Atrophy Medicine and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Spinal Muscular Atrophy Medicine that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Spinal Muscular Atrophy Medicine total production and demand, 2021-2032, (K Dose)
Global Spinal Muscular Atrophy Medicine total production value, 2021-2032, (USD Million)
Global Spinal Muscular Atrophy Medicine production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Dose), (based on production site)
Global Spinal Muscular Atrophy Medicine consumption by region & country, CAGR, 2021-2032 & (K Dose)
U.S. VS China: Spinal Muscular Atrophy Medicine domestic production, consumption, key domestic manufacturers and share
Global Spinal Muscular Atrophy Medicine production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Dose)
Global Spinal Muscular Atrophy Medicine production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
Global Spinal Muscular Atrophy Medicine production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
This report profiles key players in the global Spinal Muscular Atrophy Medicine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Biogen, Novartis, Roche, Sanofi, Ionis Pharma, Genethon, Scholar Rock, AskBio, Pfizer, PTC Therapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Spinal Muscular Atrophy Medicine market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Dose) and average price (US$/Dose) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Spinal Muscular Atrophy Medicine Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Gene Replacement Drug
- Antisense Oligonucleotide Drug
- Small Molecule Splicing Modifier Drug
- Muscle Targeted Drug
- Intrathecal Injection Drug
- Intravenous Infusion Drug
- Oral Drug
- Vector Based Drug
- Non Vector Drug
- Hospital
- Pharmacy
- Others
- Biogen
- Novartis
- Roche
- Sanofi
- Ionis Pharma
- Genethon
- Scholar Rock
- AskBio
- Pfizer
- PTC Therapeutics
- Genecradle Therapeutics
- Romics
1. How big is the global Spinal Muscular Atrophy Medicine market?
2. What is the demand of the global Spinal Muscular Atrophy Medicine market?
3. What is the year over year growth of the global Spinal Muscular Atrophy Medicine market?
4. What is the production and production value of the global Spinal Muscular Atrophy Medicine market?
5. Who are the key producers in the global Spinal Muscular Atrophy Medicine market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Spinal Muscular Atrophy Medicine Introduction
1.2 World Spinal Muscular Atrophy Medicine Supply & Forecast
1.2.1 World Spinal Muscular Atrophy Medicine Production Value (2021 & 2025 & 2032)
1.2.2 World Spinal Muscular Atrophy Medicine Production (2021-2032)
1.2.3 World Spinal Muscular Atrophy Medicine Pricing Trends (2021-2032)
1.3 World Spinal Muscular Atrophy Medicine Production by Region (Based on Production Site)
1.3.1 World Spinal Muscular Atrophy Medicine Production Value by Region (2021-2032)
1.3.2 World Spinal Muscular Atrophy Medicine Production by Region (2021-2032)
1.3.3 World Spinal Muscular Atrophy Medicine Average Price by Region (2021-2032)
1.3.4 North America Spinal Muscular Atrophy Medicine Production (2021-2032)
1.3.5 Europe Spinal Muscular Atrophy Medicine Production (2021-2032)
1.3.6 Asia Spinal Muscular Atrophy Medicine Production (2021-2032)
1.3.7 Latin America Spinal Muscular Atrophy Medicine Production (2021-2032)
1.3.8 Middle East Spinal Muscular Atrophy Medicine Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Spinal Muscular Atrophy Medicine Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Spinal Muscular Atrophy Medicine Major Market Trends
2 DEMAND SUMMARY
2.1 World Spinal Muscular Atrophy Medicine Demand (2021-2032)
2.2 World Spinal Muscular Atrophy Medicine Consumption by Region
2.2.1 World Spinal Muscular Atrophy Medicine Consumption by Region (2021-2026)
2.2.2 World Spinal Muscular Atrophy Medicine Consumption Forecast by Region (2027-2032)
2.3 United States Spinal Muscular Atrophy Medicine Consumption (2021-2032)
2.4 China Spinal Muscular Atrophy Medicine Consumption (2021-2032)
2.5 Europe Spinal Muscular Atrophy Medicine Consumption (2021-2032)
2.6 Japan Spinal Muscular Atrophy Medicine Consumption (2021-2032)
2.7 South Korea Spinal Muscular Atrophy Medicine Consumption (2021-2032)
2.8 ASEAN Spinal Muscular Atrophy Medicine Consumption (2021-2032)
2.9 India Spinal Muscular Atrophy Medicine Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Spinal Muscular Atrophy Medicine Production Value by Manufacturer (2021-2026)
3.2 World Spinal Muscular Atrophy Medicine Production by Manufacturer (2021-2026)
3.3 World Spinal Muscular Atrophy Medicine Average Price by Manufacturer (2021-2026)
3.4 Spinal Muscular Atrophy Medicine Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Spinal Muscular Atrophy Medicine Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Spinal Muscular Atrophy Medicine in 2025
3.5.3 Global Concentration Ratios (CR8) for Spinal Muscular Atrophy Medicine in 2025
3.6 Spinal Muscular Atrophy Medicine Market: Overall Company Footprint Analysis
3.6.1 Spinal Muscular Atrophy Medicine Market: Region Footprint
3.6.2 Spinal Muscular Atrophy Medicine Market: Company Product Type Footprint
3.6.3 Spinal Muscular Atrophy Medicine Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Spinal Muscular Atrophy Medicine Production Value Comparison
4.1.1 United States VS China: Spinal Muscular Atrophy Medicine Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Spinal Muscular Atrophy Medicine Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Spinal Muscular Atrophy Medicine Production Comparison
4.2.1 United States VS China: Spinal Muscular Atrophy Medicine Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Spinal Muscular Atrophy Medicine Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Spinal Muscular Atrophy Medicine Consumption Comparison
4.3.1 United States VS China: Spinal Muscular Atrophy Medicine Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Spinal Muscular Atrophy Medicine Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Spinal Muscular Atrophy Medicine Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Spinal Muscular Atrophy Medicine Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Spinal Muscular Atrophy Medicine Production Value (2021-2026)
4.4.3 United States Based Manufacturers Spinal Muscular Atrophy Medicine Production (2021-2026)
4.5 China Based Spinal Muscular Atrophy Medicine Manufacturers and Market Share
4.5.1 China Based Spinal Muscular Atrophy Medicine Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Spinal Muscular Atrophy Medicine Production Value (2021-2026)
4.5.3 China Based Manufacturers Spinal Muscular Atrophy Medicine Production (2021-2026)
4.6 Rest of World Based Spinal Muscular Atrophy Medicine Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Spinal Muscular Atrophy Medicine Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Spinal Muscular Atrophy Medicine Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Spinal Muscular Atrophy Medicine Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Spinal Muscular Atrophy Medicine Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Gene Replacement Drug
5.2.2 Antisense Oligonucleotide Drug
5.2.3 Small Molecule Splicing Modifier Drug
5.2.4 Muscle Targeted Drug
5.3 Market Segment by Type
5.3.1 World Spinal Muscular Atrophy Medicine Production by Type (2021-2032)
5.3.2 World Spinal Muscular Atrophy Medicine Production Value by Type (2021-2032)
5.3.3 World Spinal Muscular Atrophy Medicine Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY ADMINISTRATION METHOD
6.1 World Spinal Muscular Atrophy Medicine Market Size Overview by Administration Method: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Administration Method
6.2.1 Intrathecal Injection Drug
6.2.2 Intravenous Infusion Drug
6.2.3 Oral Drug
6.3 Market Segment by Administration Method
6.3.1 World Spinal Muscular Atrophy Medicine Production by Administration Method (2021-2032)
6.3.2 World Spinal Muscular Atrophy Medicine Production Value by Administration Method (2021-2032)
6.3.3 World Spinal Muscular Atrophy Medicine Average Price by Administration Method (2021-2032)
7 MARKET ANALYSIS BY DELIVERY VEHICLE
7.1 World Spinal Muscular Atrophy Medicine Market Size Overview by Delivery Vehicle: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Delivery Vehicle
7.2.1 Vector Based Drug
7.2.2 Non Vector Drug
7.3 Market Segment by Delivery Vehicle
7.3.1 World Spinal Muscular Atrophy Medicine Production by Delivery Vehicle (2021-2032)
7.3.2 World Spinal Muscular Atrophy Medicine Production Value by Delivery Vehicle (2021-2032)
7.3.3 World Spinal Muscular Atrophy Medicine Average Price by Delivery Vehicle (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Spinal Muscular Atrophy Medicine Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospital
8.2.2 Pharmacy
8.2.3 Others
8.3 Market Segment by Application
8.3.1 World Spinal Muscular Atrophy Medicine Production by Application (2021-2032)
8.3.2 World Spinal Muscular Atrophy Medicine Production Value by Application (2021-2032)
8.3.3 World Spinal Muscular Atrophy Medicine Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 Biogen
9.1.1 Biogen Details
9.1.2 Biogen Major Business
9.1.3 Biogen Spinal Muscular Atrophy Medicine Product and Services
9.1.4 Biogen Spinal Muscular Atrophy Medicine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 Biogen Recent Developments/Updates
9.1.6 Biogen Competitive Strengths & Weaknesses
9.2 Novartis
9.2.1 Novartis Details
9.2.2 Novartis Major Business
9.2.3 Novartis Spinal Muscular Atrophy Medicine Product and Services
9.2.4 Novartis Spinal Muscular Atrophy Medicine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Novartis Recent Developments/Updates
9.2.6 Novartis Competitive Strengths & Weaknesses
9.3 Roche
9.3.1 Roche Details
9.3.2 Roche Major Business
9.3.3 Roche Spinal Muscular Atrophy Medicine Product and Services
9.3.4 Roche Spinal Muscular Atrophy Medicine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Roche Recent Developments/Updates
9.3.6 Roche Competitive Strengths & Weaknesses
9.4 Sanofi
9.4.1 Sanofi Details
9.4.2 Sanofi Major Business
9.4.3 Sanofi Spinal Muscular Atrophy Medicine Product and Services
9.4.4 Sanofi Spinal Muscular Atrophy Medicine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Sanofi Recent Developments/Updates
9.4.6 Sanofi Competitive Strengths & Weaknesses
9.5 Ionis Pharma
9.5.1 Ionis Pharma Details
9.5.2 Ionis Pharma Major Business
9.5.3 Ionis Pharma Spinal Muscular Atrophy Medicine Product and Services
9.5.4 Ionis Pharma Spinal Muscular Atrophy Medicine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 Ionis Pharma Recent Developments/Updates
9.5.6 Ionis Pharma Competitive Strengths & Weaknesses
9.6 Genethon
9.6.1 Genethon Details
9.6.2 Genethon Major Business
9.6.3 Genethon Spinal Muscular Atrophy Medicine Product and Services
9.6.4 Genethon Spinal Muscular Atrophy Medicine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 Genethon Recent Developments/Updates
9.6.6 Genethon Competitive Strengths & Weaknesses
9.7 Scholar Rock
9.7.1 Scholar Rock Details
9.7.2 Scholar Rock Major Business
9.7.3 Scholar Rock Spinal Muscular Atrophy Medicine Product and Services
9.7.4 Scholar Rock Spinal Muscular Atrophy Medicine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 Scholar Rock Recent Developments/Updates
9.7.6 Scholar Rock Competitive Strengths & Weaknesses
9.8 AskBio
9.8.1 AskBio Details
9.8.2 AskBio Major Business
9.8.3 AskBio Spinal Muscular Atrophy Medicine Product and Services
9.8.4 AskBio Spinal Muscular Atrophy Medicine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 AskBio Recent Developments/Updates
9.8.6 AskBio Competitive Strengths & Weaknesses
9.9 Pfizer
9.9.1 Pfizer Details
9.9.2 Pfizer Major Business
9.9.3 Pfizer Spinal Muscular Atrophy Medicine Product and Services
9.9.4 Pfizer Spinal Muscular Atrophy Medicine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.9.5 Pfizer Recent Developments/Updates
9.9.6 Pfizer Competitive Strengths & Weaknesses
9.10 PTC Therapeutics
9.10.1 PTC Therapeutics Details
9.10.2 PTC Therapeutics Major Business
9.10.3 PTC Therapeutics Spinal Muscular Atrophy Medicine Product and Services
9.10.4 PTC Therapeutics Spinal Muscular Atrophy Medicine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.10.5 PTC Therapeutics Recent Developments/Updates
9.10.6 PTC Therapeutics Competitive Strengths & Weaknesses
9.11 Genecradle Therapeutics
9.11.1 Genecradle Therapeutics Details
9.11.2 Genecradle Therapeutics Major Business
9.11.3 Genecradle Therapeutics Spinal Muscular Atrophy Medicine Product and Services
9.11.4 Genecradle Therapeutics Spinal Muscular Atrophy Medicine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.11.5 Genecradle Therapeutics Recent Developments/Updates
9.11.6 Genecradle Therapeutics Competitive Strengths & Weaknesses
9.12 Romics
9.12.1 Romics Details
9.12.2 Romics Major Business
9.12.3 Romics Spinal Muscular Atrophy Medicine Product and Services
9.12.4 Romics Spinal Muscular Atrophy Medicine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.12.5 Romics Recent Developments/Updates
9.12.6 Romics Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Spinal Muscular Atrophy Medicine Industry Chain
10.2 Spinal Muscular Atrophy Medicine Upstream Analysis
10.2.1 Spinal Muscular Atrophy Medicine Core Raw Materials
10.2.2 Main Manufacturers of Spinal Muscular Atrophy Medicine Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Spinal Muscular Atrophy Medicine Production Mode
10.6 Spinal Muscular Atrophy Medicine Procurement Model
10.7 Spinal Muscular Atrophy Medicine Industry Sales Model and Sales Channels
10.7.1 Spinal Muscular Atrophy Medicine Sales Model
10.7.2 Spinal Muscular Atrophy Medicine Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Spinal Muscular Atrophy Medicine Introduction
1.2 World Spinal Muscular Atrophy Medicine Supply & Forecast
1.2.1 World Spinal Muscular Atrophy Medicine Production Value (2021 & 2025 & 2032)
1.2.2 World Spinal Muscular Atrophy Medicine Production (2021-2032)
1.2.3 World Spinal Muscular Atrophy Medicine Pricing Trends (2021-2032)
1.3 World Spinal Muscular Atrophy Medicine Production by Region (Based on Production Site)
1.3.1 World Spinal Muscular Atrophy Medicine Production Value by Region (2021-2032)
1.3.2 World Spinal Muscular Atrophy Medicine Production by Region (2021-2032)
1.3.3 World Spinal Muscular Atrophy Medicine Average Price by Region (2021-2032)
1.3.4 North America Spinal Muscular Atrophy Medicine Production (2021-2032)
1.3.5 Europe Spinal Muscular Atrophy Medicine Production (2021-2032)
1.3.6 Asia Spinal Muscular Atrophy Medicine Production (2021-2032)
1.3.7 Latin America Spinal Muscular Atrophy Medicine Production (2021-2032)
1.3.8 Middle East Spinal Muscular Atrophy Medicine Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Spinal Muscular Atrophy Medicine Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Spinal Muscular Atrophy Medicine Major Market Trends
2 DEMAND SUMMARY
2.1 World Spinal Muscular Atrophy Medicine Demand (2021-2032)
2.2 World Spinal Muscular Atrophy Medicine Consumption by Region
2.2.1 World Spinal Muscular Atrophy Medicine Consumption by Region (2021-2026)
2.2.2 World Spinal Muscular Atrophy Medicine Consumption Forecast by Region (2027-2032)
2.3 United States Spinal Muscular Atrophy Medicine Consumption (2021-2032)
2.4 China Spinal Muscular Atrophy Medicine Consumption (2021-2032)
2.5 Europe Spinal Muscular Atrophy Medicine Consumption (2021-2032)
2.6 Japan Spinal Muscular Atrophy Medicine Consumption (2021-2032)
2.7 South Korea Spinal Muscular Atrophy Medicine Consumption (2021-2032)
2.8 ASEAN Spinal Muscular Atrophy Medicine Consumption (2021-2032)
2.9 India Spinal Muscular Atrophy Medicine Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Spinal Muscular Atrophy Medicine Production Value by Manufacturer (2021-2026)
3.2 World Spinal Muscular Atrophy Medicine Production by Manufacturer (2021-2026)
3.3 World Spinal Muscular Atrophy Medicine Average Price by Manufacturer (2021-2026)
3.4 Spinal Muscular Atrophy Medicine Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Spinal Muscular Atrophy Medicine Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Spinal Muscular Atrophy Medicine in 2025
3.5.3 Global Concentration Ratios (CR8) for Spinal Muscular Atrophy Medicine in 2025
3.6 Spinal Muscular Atrophy Medicine Market: Overall Company Footprint Analysis
3.6.1 Spinal Muscular Atrophy Medicine Market: Region Footprint
3.6.2 Spinal Muscular Atrophy Medicine Market: Company Product Type Footprint
3.6.3 Spinal Muscular Atrophy Medicine Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Spinal Muscular Atrophy Medicine Production Value Comparison
4.1.1 United States VS China: Spinal Muscular Atrophy Medicine Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Spinal Muscular Atrophy Medicine Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Spinal Muscular Atrophy Medicine Production Comparison
4.2.1 United States VS China: Spinal Muscular Atrophy Medicine Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Spinal Muscular Atrophy Medicine Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Spinal Muscular Atrophy Medicine Consumption Comparison
4.3.1 United States VS China: Spinal Muscular Atrophy Medicine Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Spinal Muscular Atrophy Medicine Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Spinal Muscular Atrophy Medicine Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Spinal Muscular Atrophy Medicine Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Spinal Muscular Atrophy Medicine Production Value (2021-2026)
4.4.3 United States Based Manufacturers Spinal Muscular Atrophy Medicine Production (2021-2026)
4.5 China Based Spinal Muscular Atrophy Medicine Manufacturers and Market Share
4.5.1 China Based Spinal Muscular Atrophy Medicine Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Spinal Muscular Atrophy Medicine Production Value (2021-2026)
4.5.3 China Based Manufacturers Spinal Muscular Atrophy Medicine Production (2021-2026)
4.6 Rest of World Based Spinal Muscular Atrophy Medicine Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Spinal Muscular Atrophy Medicine Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Spinal Muscular Atrophy Medicine Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Spinal Muscular Atrophy Medicine Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Spinal Muscular Atrophy Medicine Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Gene Replacement Drug
5.2.2 Antisense Oligonucleotide Drug
5.2.3 Small Molecule Splicing Modifier Drug
5.2.4 Muscle Targeted Drug
5.3 Market Segment by Type
5.3.1 World Spinal Muscular Atrophy Medicine Production by Type (2021-2032)
5.3.2 World Spinal Muscular Atrophy Medicine Production Value by Type (2021-2032)
5.3.3 World Spinal Muscular Atrophy Medicine Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY ADMINISTRATION METHOD
6.1 World Spinal Muscular Atrophy Medicine Market Size Overview by Administration Method: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Administration Method
6.2.1 Intrathecal Injection Drug
6.2.2 Intravenous Infusion Drug
6.2.3 Oral Drug
6.3 Market Segment by Administration Method
6.3.1 World Spinal Muscular Atrophy Medicine Production by Administration Method (2021-2032)
6.3.2 World Spinal Muscular Atrophy Medicine Production Value by Administration Method (2021-2032)
6.3.3 World Spinal Muscular Atrophy Medicine Average Price by Administration Method (2021-2032)
7 MARKET ANALYSIS BY DELIVERY VEHICLE
7.1 World Spinal Muscular Atrophy Medicine Market Size Overview by Delivery Vehicle: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Delivery Vehicle
7.2.1 Vector Based Drug
7.2.2 Non Vector Drug
7.3 Market Segment by Delivery Vehicle
7.3.1 World Spinal Muscular Atrophy Medicine Production by Delivery Vehicle (2021-2032)
7.3.2 World Spinal Muscular Atrophy Medicine Production Value by Delivery Vehicle (2021-2032)
7.3.3 World Spinal Muscular Atrophy Medicine Average Price by Delivery Vehicle (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Spinal Muscular Atrophy Medicine Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospital
8.2.2 Pharmacy
8.2.3 Others
8.3 Market Segment by Application
8.3.1 World Spinal Muscular Atrophy Medicine Production by Application (2021-2032)
8.3.2 World Spinal Muscular Atrophy Medicine Production Value by Application (2021-2032)
8.3.3 World Spinal Muscular Atrophy Medicine Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 Biogen
9.1.1 Biogen Details
9.1.2 Biogen Major Business
9.1.3 Biogen Spinal Muscular Atrophy Medicine Product and Services
9.1.4 Biogen Spinal Muscular Atrophy Medicine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 Biogen Recent Developments/Updates
9.1.6 Biogen Competitive Strengths & Weaknesses
9.2 Novartis
9.2.1 Novartis Details
9.2.2 Novartis Major Business
9.2.3 Novartis Spinal Muscular Atrophy Medicine Product and Services
9.2.4 Novartis Spinal Muscular Atrophy Medicine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Novartis Recent Developments/Updates
9.2.6 Novartis Competitive Strengths & Weaknesses
9.3 Roche
9.3.1 Roche Details
9.3.2 Roche Major Business
9.3.3 Roche Spinal Muscular Atrophy Medicine Product and Services
9.3.4 Roche Spinal Muscular Atrophy Medicine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Roche Recent Developments/Updates
9.3.6 Roche Competitive Strengths & Weaknesses
9.4 Sanofi
9.4.1 Sanofi Details
9.4.2 Sanofi Major Business
9.4.3 Sanofi Spinal Muscular Atrophy Medicine Product and Services
9.4.4 Sanofi Spinal Muscular Atrophy Medicine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Sanofi Recent Developments/Updates
9.4.6 Sanofi Competitive Strengths & Weaknesses
9.5 Ionis Pharma
9.5.1 Ionis Pharma Details
9.5.2 Ionis Pharma Major Business
9.5.3 Ionis Pharma Spinal Muscular Atrophy Medicine Product and Services
9.5.4 Ionis Pharma Spinal Muscular Atrophy Medicine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 Ionis Pharma Recent Developments/Updates
9.5.6 Ionis Pharma Competitive Strengths & Weaknesses
9.6 Genethon
9.6.1 Genethon Details
9.6.2 Genethon Major Business
9.6.3 Genethon Spinal Muscular Atrophy Medicine Product and Services
9.6.4 Genethon Spinal Muscular Atrophy Medicine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 Genethon Recent Developments/Updates
9.6.6 Genethon Competitive Strengths & Weaknesses
9.7 Scholar Rock
9.7.1 Scholar Rock Details
9.7.2 Scholar Rock Major Business
9.7.3 Scholar Rock Spinal Muscular Atrophy Medicine Product and Services
9.7.4 Scholar Rock Spinal Muscular Atrophy Medicine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 Scholar Rock Recent Developments/Updates
9.7.6 Scholar Rock Competitive Strengths & Weaknesses
9.8 AskBio
9.8.1 AskBio Details
9.8.2 AskBio Major Business
9.8.3 AskBio Spinal Muscular Atrophy Medicine Product and Services
9.8.4 AskBio Spinal Muscular Atrophy Medicine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 AskBio Recent Developments/Updates
9.8.6 AskBio Competitive Strengths & Weaknesses
9.9 Pfizer
9.9.1 Pfizer Details
9.9.2 Pfizer Major Business
9.9.3 Pfizer Spinal Muscular Atrophy Medicine Product and Services
9.9.4 Pfizer Spinal Muscular Atrophy Medicine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.9.5 Pfizer Recent Developments/Updates
9.9.6 Pfizer Competitive Strengths & Weaknesses
9.10 PTC Therapeutics
9.10.1 PTC Therapeutics Details
9.10.2 PTC Therapeutics Major Business
9.10.3 PTC Therapeutics Spinal Muscular Atrophy Medicine Product and Services
9.10.4 PTC Therapeutics Spinal Muscular Atrophy Medicine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.10.5 PTC Therapeutics Recent Developments/Updates
9.10.6 PTC Therapeutics Competitive Strengths & Weaknesses
9.11 Genecradle Therapeutics
9.11.1 Genecradle Therapeutics Details
9.11.2 Genecradle Therapeutics Major Business
9.11.3 Genecradle Therapeutics Spinal Muscular Atrophy Medicine Product and Services
9.11.4 Genecradle Therapeutics Spinal Muscular Atrophy Medicine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.11.5 Genecradle Therapeutics Recent Developments/Updates
9.11.6 Genecradle Therapeutics Competitive Strengths & Weaknesses
9.12 Romics
9.12.1 Romics Details
9.12.2 Romics Major Business
9.12.3 Romics Spinal Muscular Atrophy Medicine Product and Services
9.12.4 Romics Spinal Muscular Atrophy Medicine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.12.5 Romics Recent Developments/Updates
9.12.6 Romics Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Spinal Muscular Atrophy Medicine Industry Chain
10.2 Spinal Muscular Atrophy Medicine Upstream Analysis
10.2.1 Spinal Muscular Atrophy Medicine Core Raw Materials
10.2.2 Main Manufacturers of Spinal Muscular Atrophy Medicine Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Spinal Muscular Atrophy Medicine Production Mode
10.6 Spinal Muscular Atrophy Medicine Procurement Model
10.7 Spinal Muscular Atrophy Medicine Industry Sales Model and Sales Channels
10.7.1 Spinal Muscular Atrophy Medicine Sales Model
10.7.2 Spinal Muscular Atrophy Medicine Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Spinal Muscular Atrophy Medicine Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Spinal Muscular Atrophy Medicine Production Value by Region (2021-2026) & (USD Million)
Table 3. World Spinal Muscular Atrophy Medicine Production Value by Region (2027-2032) & (USD Million)
Table 4. World Spinal Muscular Atrophy Medicine Production Value Market Share by Region (2021-2026)
Table 5. World Spinal Muscular Atrophy Medicine Production Value Market Share by Region (2027-2032)
Table 6. World Spinal Muscular Atrophy Medicine Production by Region (2021-2026) & (K Dose)
Table 7. World Spinal Muscular Atrophy Medicine Production by Region (2027-2032) & (K Dose)
Table 8. World Spinal Muscular Atrophy Medicine Production Market Share by Region (2021-2026)
Table 9. World Spinal Muscular Atrophy Medicine Production Market Share by Region (2027-2032)
Table 10. World Spinal Muscular Atrophy Medicine Average Price by Region (2021-2026) & (US$/Dose)
Table 11. World Spinal Muscular Atrophy Medicine Average Price by Region (2027-2032) & (US$/Dose)
Table 12. Spinal Muscular Atrophy Medicine Major Market Trends
Table 13. World Spinal Muscular Atrophy Medicine Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Dose)
Table 14. World Spinal Muscular Atrophy Medicine Consumption by Region (2021-2026) & (K Dose)
Table 15. World Spinal Muscular Atrophy Medicine Consumption Forecast by Region (2027-2032) & (K Dose)
Table 16. World Spinal Muscular Atrophy Medicine Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Spinal Muscular Atrophy Medicine Producers in 2025
Table 18. World Spinal Muscular Atrophy Medicine Production by Manufacturer (2021-2026) & (K Dose)
Table 19. Production Market Share of Key Spinal Muscular Atrophy Medicine Producers in 2025
Table 20. World Spinal Muscular Atrophy Medicine Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 21. Global Spinal Muscular Atrophy Medicine Company Evaluation Quadrant
Table 22. World Spinal Muscular Atrophy Medicine Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Spinal Muscular Atrophy Medicine Production Site of Key Manufacturer
Table 24. Spinal Muscular Atrophy Medicine Market: Company Product Type Footprint
Table 25. Spinal Muscular Atrophy Medicine Market: Company Product Application Footprint
Table 26. Spinal Muscular Atrophy Medicine Competitive Factors
Table 27. Spinal Muscular Atrophy Medicine New Entrant and Capacity Expansion Plans
Table 28. Spinal Muscular Atrophy Medicine Mergers & Acquisitions Activity
Table 29. United States VS China Spinal Muscular Atrophy Medicine Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Spinal Muscular Atrophy Medicine Production Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 31. United States VS China Spinal Muscular Atrophy Medicine Consumption Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 32. United States Based Spinal Muscular Atrophy Medicine Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Spinal Muscular Atrophy Medicine Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Spinal Muscular Atrophy Medicine Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Spinal Muscular Atrophy Medicine Production (2021-2026) & (K Dose)
Table 36. United States Based Manufacturers Spinal Muscular Atrophy Medicine Production Market Share (2021-2026)
Table 37. China Based Spinal Muscular Atrophy Medicine Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Spinal Muscular Atrophy Medicine Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Spinal Muscular Atrophy Medicine Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Spinal Muscular Atrophy Medicine Production, (2021-2026) & (K Dose)
Table 41. China Based Manufacturers Spinal Muscular Atrophy Medicine Production Market Share (2021-2026)
Table 42. Rest of World Based Spinal Muscular Atrophy Medicine Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Spinal Muscular Atrophy Medicine Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Spinal Muscular Atrophy Medicine Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Spinal Muscular Atrophy Medicine Production, (2021-2026) & (K Dose)
Table 46. Rest of World Based Manufacturers Spinal Muscular Atrophy Medicine Production Market Share (2021-2026)
Table 47. World Spinal Muscular Atrophy Medicine Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Spinal Muscular Atrophy Medicine Production by Type (2021-2026) & (K Dose)
Table 49. World Spinal Muscular Atrophy Medicine Production by Type (2027-2032) & (K Dose)
Table 50. World Spinal Muscular Atrophy Medicine Production Value by Type (2021-2026) & (USD Million)
Table 51. World Spinal Muscular Atrophy Medicine Production Value by Type (2027-2032) & (USD Million)
Table 52. World Spinal Muscular Atrophy Medicine Average Price by Type (2021-2026) & (US$/Dose)
Table 53. World Spinal Muscular Atrophy Medicine Average Price by Type (2027-2032) & (US$/Dose)
Table 54. World Spinal Muscular Atrophy Medicine Production Value by Administration Method, (USD Million), 2021 & 2025 & 2032
Table 55. World Spinal Muscular Atrophy Medicine Production by Administration Method (2021-2026) & (K Dose)
Table 56. World Spinal Muscular Atrophy Medicine Production by Administration Method (2027-2032) & (K Dose)
Table 57. World Spinal Muscular Atrophy Medicine Production Value by Administration Method (2021-2026) & (USD Million)
Table 58. World Spinal Muscular Atrophy Medicine Production Value by Administration Method (2027-2032) & (USD Million)
Table 59. World Spinal Muscular Atrophy Medicine Average Price by Administration Method (2021-2026) & (US$/Dose)
Table 60. World Spinal Muscular Atrophy Medicine Average Price by Administration Method (2027-2032) & (US$/Dose)
Table 61. World Spinal Muscular Atrophy Medicine Production Value by Delivery Vehicle, (USD Million), 2021 & 2025 & 2032
Table 62. World Spinal Muscular Atrophy Medicine Production by Delivery Vehicle (2021-2026) & (K Dose)
Table 63. World Spinal Muscular Atrophy Medicine Production by Delivery Vehicle (2027-2032) & (K Dose)
Table 64. World Spinal Muscular Atrophy Medicine Production Value by Delivery Vehicle (2021-2026) & (USD Million)
Table 65. World Spinal Muscular Atrophy Medicine Production Value by Delivery Vehicle (2027-2032) & (USD Million)
Table 66. World Spinal Muscular Atrophy Medicine Average Price by Delivery Vehicle (2021-2026) & (US$/Dose)
Table 67. World Spinal Muscular Atrophy Medicine Average Price by Delivery Vehicle (2027-2032) & (US$/Dose)
Table 68. World Spinal Muscular Atrophy Medicine Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Spinal Muscular Atrophy Medicine Production by Application (2021-2026) & (K Dose)
Table 70. World Spinal Muscular Atrophy Medicine Production by Application (2027-2032) & (K Dose)
Table 71. World Spinal Muscular Atrophy Medicine Production Value by Application (2021-2026) & (USD Million)
Table 72. World Spinal Muscular Atrophy Medicine Production Value by Application (2027-2032) & (USD Million)
Table 73. World Spinal Muscular Atrophy Medicine Average Price by Application (2021-2026) & (US$/Dose)
Table 74. World Spinal Muscular Atrophy Medicine Average Price by Application (2027-2032) & (US$/Dose)
Table 75. Biogen Basic Information, Manufacturing Base and Competitors
Table 76. Biogen Major Business
Table 77. Biogen Spinal Muscular Atrophy Medicine Product and Services
Table 78. Biogen Spinal Muscular Atrophy Medicine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Biogen Recent Developments/Updates
Table 80. Biogen Competitive Strengths & Weaknesses
Table 81. Novartis Basic Information, Manufacturing Base and Competitors
Table 82. Novartis Major Business
Table 83. Novartis Spinal Muscular Atrophy Medicine Product and Services
Table 84. Novartis Spinal Muscular Atrophy Medicine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Novartis Recent Developments/Updates
Table 86. Novartis Competitive Strengths & Weaknesses
Table 87. Roche Basic Information, Manufacturing Base and Competitors
Table 88. Roche Major Business
Table 89. Roche Spinal Muscular Atrophy Medicine Product and Services
Table 90. Roche Spinal Muscular Atrophy Medicine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Roche Recent Developments/Updates
Table 92. Roche Competitive Strengths & Weaknesses
Table 93. Sanofi Basic Information, Manufacturing Base and Competitors
Table 94. Sanofi Major Business
Table 95. Sanofi Spinal Muscular Atrophy Medicine Product and Services
Table 96. Sanofi Spinal Muscular Atrophy Medicine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Sanofi Recent Developments/Updates
Table 98. Sanofi Competitive Strengths & Weaknesses
Table 99. Ionis Pharma Basic Information, Manufacturing Base and Competitors
Table 100. Ionis Pharma Major Business
Table 101. Ionis Pharma Spinal Muscular Atrophy Medicine Product and Services
Table 102. Ionis Pharma Spinal Muscular Atrophy Medicine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Ionis Pharma Recent Developments/Updates
Table 104. Ionis Pharma Competitive Strengths & Weaknesses
Table 105. Genethon Basic Information, Manufacturing Base and Competitors
Table 106. Genethon Major Business
Table 107. Genethon Spinal Muscular Atrophy Medicine Product and Services
Table 108. Genethon Spinal Muscular Atrophy Medicine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. Genethon Recent Developments/Updates
Table 110. Genethon Competitive Strengths & Weaknesses
Table 111. Scholar Rock Basic Information, Manufacturing Base and Competitors
Table 112. Scholar Rock Major Business
Table 113. Scholar Rock Spinal Muscular Atrophy Medicine Product and Services
Table 114. Scholar Rock Spinal Muscular Atrophy Medicine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Scholar Rock Recent Developments/Updates
Table 116. Scholar Rock Competitive Strengths & Weaknesses
Table 117. AskBio Basic Information, Manufacturing Base and Competitors
Table 118. AskBio Major Business
Table 119. AskBio Spinal Muscular Atrophy Medicine Product and Services
Table 120. AskBio Spinal Muscular Atrophy Medicine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. AskBio Recent Developments/Updates
Table 122. AskBio Competitive Strengths & Weaknesses
Table 123. Pfizer Basic Information, Manufacturing Base and Competitors
Table 124. Pfizer Major Business
Table 125. Pfizer Spinal Muscular Atrophy Medicine Product and Services
Table 126. Pfizer Spinal Muscular Atrophy Medicine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 127. Pfizer Recent Developments/Updates
Table 128. Pfizer Competitive Strengths & Weaknesses
Table 129. PTC Therapeutics Basic Information, Manufacturing Base and Competitors
Table 130. PTC Therapeutics Major Business
Table 131. PTC Therapeutics Spinal Muscular Atrophy Medicine Product and Services
Table 132. PTC Therapeutics Spinal Muscular Atrophy Medicine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 133. PTC Therapeutics Recent Developments/Updates
Table 134. PTC Therapeutics Competitive Strengths & Weaknesses
Table 135. Genecradle Therapeutics Basic Information, Manufacturing Base and Competitors
Table 136. Genecradle Therapeutics Major Business
Table 137. Genecradle Therapeutics Spinal Muscular Atrophy Medicine Product and Services
Table 138. Genecradle Therapeutics Spinal Muscular Atrophy Medicine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 139. Genecradle Therapeutics Recent Developments/Updates
Table 140. Genecradle Therapeutics Competitive Strengths & Weaknesses
Table 141. Romics Basic Information, Manufacturing Base and Competitors
Table 142. Romics Major Business
Table 143. Romics Spinal Muscular Atrophy Medicine Product and Services
Table 144. Romics Spinal Muscular Atrophy Medicine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. Romics Recent Developments/Updates
Table 146. Romics Competitive Strengths & Weaknesses
Table 147. Global Key Players of Spinal Muscular Atrophy Medicine Upstream (Raw Materials)
Table 148. Global Spinal Muscular Atrophy Medicine Typical Customers
Table 149. Spinal Muscular Atrophy Medicine Typical Distributors
Table 1. World Spinal Muscular Atrophy Medicine Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Spinal Muscular Atrophy Medicine Production Value by Region (2021-2026) & (USD Million)
Table 3. World Spinal Muscular Atrophy Medicine Production Value by Region (2027-2032) & (USD Million)
Table 4. World Spinal Muscular Atrophy Medicine Production Value Market Share by Region (2021-2026)
Table 5. World Spinal Muscular Atrophy Medicine Production Value Market Share by Region (2027-2032)
Table 6. World Spinal Muscular Atrophy Medicine Production by Region (2021-2026) & (K Dose)
Table 7. World Spinal Muscular Atrophy Medicine Production by Region (2027-2032) & (K Dose)
Table 8. World Spinal Muscular Atrophy Medicine Production Market Share by Region (2021-2026)
Table 9. World Spinal Muscular Atrophy Medicine Production Market Share by Region (2027-2032)
Table 10. World Spinal Muscular Atrophy Medicine Average Price by Region (2021-2026) & (US$/Dose)
Table 11. World Spinal Muscular Atrophy Medicine Average Price by Region (2027-2032) & (US$/Dose)
Table 12. Spinal Muscular Atrophy Medicine Major Market Trends
Table 13. World Spinal Muscular Atrophy Medicine Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Dose)
Table 14. World Spinal Muscular Atrophy Medicine Consumption by Region (2021-2026) & (K Dose)
Table 15. World Spinal Muscular Atrophy Medicine Consumption Forecast by Region (2027-2032) & (K Dose)
Table 16. World Spinal Muscular Atrophy Medicine Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Spinal Muscular Atrophy Medicine Producers in 2025
Table 18. World Spinal Muscular Atrophy Medicine Production by Manufacturer (2021-2026) & (K Dose)
Table 19. Production Market Share of Key Spinal Muscular Atrophy Medicine Producers in 2025
Table 20. World Spinal Muscular Atrophy Medicine Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 21. Global Spinal Muscular Atrophy Medicine Company Evaluation Quadrant
Table 22. World Spinal Muscular Atrophy Medicine Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Spinal Muscular Atrophy Medicine Production Site of Key Manufacturer
Table 24. Spinal Muscular Atrophy Medicine Market: Company Product Type Footprint
Table 25. Spinal Muscular Atrophy Medicine Market: Company Product Application Footprint
Table 26. Spinal Muscular Atrophy Medicine Competitive Factors
Table 27. Spinal Muscular Atrophy Medicine New Entrant and Capacity Expansion Plans
Table 28. Spinal Muscular Atrophy Medicine Mergers & Acquisitions Activity
Table 29. United States VS China Spinal Muscular Atrophy Medicine Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Spinal Muscular Atrophy Medicine Production Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 31. United States VS China Spinal Muscular Atrophy Medicine Consumption Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 32. United States Based Spinal Muscular Atrophy Medicine Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Spinal Muscular Atrophy Medicine Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Spinal Muscular Atrophy Medicine Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Spinal Muscular Atrophy Medicine Production (2021-2026) & (K Dose)
Table 36. United States Based Manufacturers Spinal Muscular Atrophy Medicine Production Market Share (2021-2026)
Table 37. China Based Spinal Muscular Atrophy Medicine Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Spinal Muscular Atrophy Medicine Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Spinal Muscular Atrophy Medicine Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Spinal Muscular Atrophy Medicine Production, (2021-2026) & (K Dose)
Table 41. China Based Manufacturers Spinal Muscular Atrophy Medicine Production Market Share (2021-2026)
Table 42. Rest of World Based Spinal Muscular Atrophy Medicine Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Spinal Muscular Atrophy Medicine Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Spinal Muscular Atrophy Medicine Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Spinal Muscular Atrophy Medicine Production, (2021-2026) & (K Dose)
Table 46. Rest of World Based Manufacturers Spinal Muscular Atrophy Medicine Production Market Share (2021-2026)
Table 47. World Spinal Muscular Atrophy Medicine Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Spinal Muscular Atrophy Medicine Production by Type (2021-2026) & (K Dose)
Table 49. World Spinal Muscular Atrophy Medicine Production by Type (2027-2032) & (K Dose)
Table 50. World Spinal Muscular Atrophy Medicine Production Value by Type (2021-2026) & (USD Million)
Table 51. World Spinal Muscular Atrophy Medicine Production Value by Type (2027-2032) & (USD Million)
Table 52. World Spinal Muscular Atrophy Medicine Average Price by Type (2021-2026) & (US$/Dose)
Table 53. World Spinal Muscular Atrophy Medicine Average Price by Type (2027-2032) & (US$/Dose)
Table 54. World Spinal Muscular Atrophy Medicine Production Value by Administration Method, (USD Million), 2021 & 2025 & 2032
Table 55. World Spinal Muscular Atrophy Medicine Production by Administration Method (2021-2026) & (K Dose)
Table 56. World Spinal Muscular Atrophy Medicine Production by Administration Method (2027-2032) & (K Dose)
Table 57. World Spinal Muscular Atrophy Medicine Production Value by Administration Method (2021-2026) & (USD Million)
Table 58. World Spinal Muscular Atrophy Medicine Production Value by Administration Method (2027-2032) & (USD Million)
Table 59. World Spinal Muscular Atrophy Medicine Average Price by Administration Method (2021-2026) & (US$/Dose)
Table 60. World Spinal Muscular Atrophy Medicine Average Price by Administration Method (2027-2032) & (US$/Dose)
Table 61. World Spinal Muscular Atrophy Medicine Production Value by Delivery Vehicle, (USD Million), 2021 & 2025 & 2032
Table 62. World Spinal Muscular Atrophy Medicine Production by Delivery Vehicle (2021-2026) & (K Dose)
Table 63. World Spinal Muscular Atrophy Medicine Production by Delivery Vehicle (2027-2032) & (K Dose)
Table 64. World Spinal Muscular Atrophy Medicine Production Value by Delivery Vehicle (2021-2026) & (USD Million)
Table 65. World Spinal Muscular Atrophy Medicine Production Value by Delivery Vehicle (2027-2032) & (USD Million)
Table 66. World Spinal Muscular Atrophy Medicine Average Price by Delivery Vehicle (2021-2026) & (US$/Dose)
Table 67. World Spinal Muscular Atrophy Medicine Average Price by Delivery Vehicle (2027-2032) & (US$/Dose)
Table 68. World Spinal Muscular Atrophy Medicine Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Spinal Muscular Atrophy Medicine Production by Application (2021-2026) & (K Dose)
Table 70. World Spinal Muscular Atrophy Medicine Production by Application (2027-2032) & (K Dose)
Table 71. World Spinal Muscular Atrophy Medicine Production Value by Application (2021-2026) & (USD Million)
Table 72. World Spinal Muscular Atrophy Medicine Production Value by Application (2027-2032) & (USD Million)
Table 73. World Spinal Muscular Atrophy Medicine Average Price by Application (2021-2026) & (US$/Dose)
Table 74. World Spinal Muscular Atrophy Medicine Average Price by Application (2027-2032) & (US$/Dose)
Table 75. Biogen Basic Information, Manufacturing Base and Competitors
Table 76. Biogen Major Business
Table 77. Biogen Spinal Muscular Atrophy Medicine Product and Services
Table 78. Biogen Spinal Muscular Atrophy Medicine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Biogen Recent Developments/Updates
Table 80. Biogen Competitive Strengths & Weaknesses
Table 81. Novartis Basic Information, Manufacturing Base and Competitors
Table 82. Novartis Major Business
Table 83. Novartis Spinal Muscular Atrophy Medicine Product and Services
Table 84. Novartis Spinal Muscular Atrophy Medicine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Novartis Recent Developments/Updates
Table 86. Novartis Competitive Strengths & Weaknesses
Table 87. Roche Basic Information, Manufacturing Base and Competitors
Table 88. Roche Major Business
Table 89. Roche Spinal Muscular Atrophy Medicine Product and Services
Table 90. Roche Spinal Muscular Atrophy Medicine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Roche Recent Developments/Updates
Table 92. Roche Competitive Strengths & Weaknesses
Table 93. Sanofi Basic Information, Manufacturing Base and Competitors
Table 94. Sanofi Major Business
Table 95. Sanofi Spinal Muscular Atrophy Medicine Product and Services
Table 96. Sanofi Spinal Muscular Atrophy Medicine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Sanofi Recent Developments/Updates
Table 98. Sanofi Competitive Strengths & Weaknesses
Table 99. Ionis Pharma Basic Information, Manufacturing Base and Competitors
Table 100. Ionis Pharma Major Business
Table 101. Ionis Pharma Spinal Muscular Atrophy Medicine Product and Services
Table 102. Ionis Pharma Spinal Muscular Atrophy Medicine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Ionis Pharma Recent Developments/Updates
Table 104. Ionis Pharma Competitive Strengths & Weaknesses
Table 105. Genethon Basic Information, Manufacturing Base and Competitors
Table 106. Genethon Major Business
Table 107. Genethon Spinal Muscular Atrophy Medicine Product and Services
Table 108. Genethon Spinal Muscular Atrophy Medicine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. Genethon Recent Developments/Updates
Table 110. Genethon Competitive Strengths & Weaknesses
Table 111. Scholar Rock Basic Information, Manufacturing Base and Competitors
Table 112. Scholar Rock Major Business
Table 113. Scholar Rock Spinal Muscular Atrophy Medicine Product and Services
Table 114. Scholar Rock Spinal Muscular Atrophy Medicine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Scholar Rock Recent Developments/Updates
Table 116. Scholar Rock Competitive Strengths & Weaknesses
Table 117. AskBio Basic Information, Manufacturing Base and Competitors
Table 118. AskBio Major Business
Table 119. AskBio Spinal Muscular Atrophy Medicine Product and Services
Table 120. AskBio Spinal Muscular Atrophy Medicine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. AskBio Recent Developments/Updates
Table 122. AskBio Competitive Strengths & Weaknesses
Table 123. Pfizer Basic Information, Manufacturing Base and Competitors
Table 124. Pfizer Major Business
Table 125. Pfizer Spinal Muscular Atrophy Medicine Product and Services
Table 126. Pfizer Spinal Muscular Atrophy Medicine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 127. Pfizer Recent Developments/Updates
Table 128. Pfizer Competitive Strengths & Weaknesses
Table 129. PTC Therapeutics Basic Information, Manufacturing Base and Competitors
Table 130. PTC Therapeutics Major Business
Table 131. PTC Therapeutics Spinal Muscular Atrophy Medicine Product and Services
Table 132. PTC Therapeutics Spinal Muscular Atrophy Medicine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 133. PTC Therapeutics Recent Developments/Updates
Table 134. PTC Therapeutics Competitive Strengths & Weaknesses
Table 135. Genecradle Therapeutics Basic Information, Manufacturing Base and Competitors
Table 136. Genecradle Therapeutics Major Business
Table 137. Genecradle Therapeutics Spinal Muscular Atrophy Medicine Product and Services
Table 138. Genecradle Therapeutics Spinal Muscular Atrophy Medicine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 139. Genecradle Therapeutics Recent Developments/Updates
Table 140. Genecradle Therapeutics Competitive Strengths & Weaknesses
Table 141. Romics Basic Information, Manufacturing Base and Competitors
Table 142. Romics Major Business
Table 143. Romics Spinal Muscular Atrophy Medicine Product and Services
Table 144. Romics Spinal Muscular Atrophy Medicine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. Romics Recent Developments/Updates
Table 146. Romics Competitive Strengths & Weaknesses
Table 147. Global Key Players of Spinal Muscular Atrophy Medicine Upstream (Raw Materials)
Table 148. Global Spinal Muscular Atrophy Medicine Typical Customers
Table 149. Spinal Muscular Atrophy Medicine Typical Distributors
LIST OF FIGURES
Figure 1. Spinal Muscular Atrophy Medicine Picture
Figure 2. World Spinal Muscular Atrophy Medicine Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Spinal Muscular Atrophy Medicine Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Spinal Muscular Atrophy Medicine Production (2021-2032) & (K Dose)
Figure 5. World Spinal Muscular Atrophy Medicine Average Price (2021-2032) & (US$/Dose)
Figure 6. World Spinal Muscular Atrophy Medicine Production Value Market Share by Region (2021-2032)
Figure 7. World Spinal Muscular Atrophy Medicine Production Market Share by Region (2021-2032)
Figure 8. North America Spinal Muscular Atrophy Medicine Production (2021-2032) & (K Dose)
Figure 9. Europe Spinal Muscular Atrophy Medicine Production (2021-2032) & (K Dose)
Figure 10. Asia Spinal Muscular Atrophy Medicine Production (2021-2032) & (K Dose)
Figure 11. Latin America Spinal Muscular Atrophy Medicine Production (2021-2032) & (K Dose)
Figure 12. Middle East Spinal Muscular Atrophy Medicine Production (2021-2032) & (K Dose)
Figure 13. Spinal Muscular Atrophy Medicine Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Spinal Muscular Atrophy Medicine Consumption (2021-2032) & (K Dose)
Figure 16. World Spinal Muscular Atrophy Medicine Consumption Market Share by Region (2021-2032)
Figure 17. United States Spinal Muscular Atrophy Medicine Consumption (2021-2032) & (K Dose)
Figure 18. China Spinal Muscular Atrophy Medicine Consumption (2021-2032) & (K Dose)
Figure 19. Europe Spinal Muscular Atrophy Medicine Consumption (2021-2032) & (K Dose)
Figure 20. Japan Spinal Muscular Atrophy Medicine Consumption (2021-2032) & (K Dose)
Figure 21. South Korea Spinal Muscular Atrophy Medicine Consumption (2021-2032) & (K Dose)
Figure 22. ASEAN Spinal Muscular Atrophy Medicine Consumption (2021-2032) & (K Dose)
Figure 23. India Spinal Muscular Atrophy Medicine Consumption (2021-2032) & (K Dose)
Figure 24. Producer Shipments of Spinal Muscular Atrophy Medicine by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Spinal Muscular Atrophy Medicine Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Spinal Muscular Atrophy Medicine Markets in 2025
Figure 27. United States VS China: Spinal Muscular Atrophy Medicine Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Spinal Muscular Atrophy Medicine Production Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States VS China: Spinal Muscular Atrophy Medicine Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 30. United States Based Manufacturers Spinal Muscular Atrophy Medicine Production Market Share 2025
Figure 31. China Based Manufacturers Spinal Muscular Atrophy Medicine Production Market Share 2025
Figure 32. Rest of World Based Manufacturers Spinal Muscular Atrophy Medicine Production Market Share 2025
Figure 33. World Spinal Muscular Atrophy Medicine Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 34. World Spinal Muscular Atrophy Medicine Production Value Market Share by Type in 2025
Figure 35. Gene Replacement Drug
Figure 36. Antisense Oligonucleotide Drug
Figure 37. Small Molecule Splicing Modifier Drug
Figure 38. Muscle Targeted Drug
Figure 39. World Spinal Muscular Atrophy Medicine Production Market Share by Type (2021-2032)
Figure 40. World Spinal Muscular Atrophy Medicine Production Value Market Share by Type (2021-2032)
Figure 41. World Spinal Muscular Atrophy Medicine Average Price by Type (2021-2032) & (US$/Dose)
Figure 42. World Spinal Muscular Atrophy Medicine Production Value by Administration Method, (USD Million), 2021 & 2025 & 2032
Figure 43. World Spinal Muscular Atrophy Medicine Production Value Market Share by Administration Method in 2025
Figure 44. Intrathecal Injection Drug
Figure 45. Intravenous Infusion Drug
Figure 46. Oral Drug
Figure 47. World Spinal Muscular Atrophy Medicine Production Market Share by Administration Method (2021-2032)
Figure 48. World Spinal Muscular Atrophy Medicine Production Value Market Share by Administration Method (2021-2032)
Figure 49. World Spinal Muscular Atrophy Medicine Average Price by Administration Method (2021-2032) & (US$/Dose)
Figure 50. World Spinal Muscular Atrophy Medicine Production Value by Delivery Vehicle, (USD Million), 2021 & 2025 & 2032
Figure 51. World Spinal Muscular Atrophy Medicine Production Value Market Share by Delivery Vehicle in 2025
Figure 52. Vector Based Drug
Figure 53. Non Vector Drug
Figure 54. World Spinal Muscular Atrophy Medicine Production Market Share by Delivery Vehicle (2021-2032)
Figure 55. World Spinal Muscular Atrophy Medicine Production Value Market Share by Delivery Vehicle (2021-2032)
Figure 56. World Spinal Muscular Atrophy Medicine Average Price by Delivery Vehicle (2021-2032) & (US$/Dose)
Figure 57. World Spinal Muscular Atrophy Medicine Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 58. World Spinal Muscular Atrophy Medicine Production Value Market Share by Application in 2025
Figure 59. Hospital
Figure 60. Pharmacy
Figure 61. Others
Figure 62. World Spinal Muscular Atrophy Medicine Production Market Share by Application (2021-2032)
Figure 63. World Spinal Muscular Atrophy Medicine Production Value Market Share by Application (2021-2032)
Figure 64. World Spinal Muscular Atrophy Medicine Average Price by Application (2021-2032) & (US$/Dose)
Figure 65. Spinal Muscular Atrophy Medicine Industry Chain
Figure 66. Spinal Muscular Atrophy Medicine Procurement Model
Figure 67. Spinal Muscular Atrophy Medicine Sales Model
Figure 68. Spinal Muscular Atrophy Medicine Sales Channels, Direct Sales, and Distribution
Figure 69. Methodology
Figure 70. Research Process and Data Source
Figure 1. Spinal Muscular Atrophy Medicine Picture
Figure 2. World Spinal Muscular Atrophy Medicine Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Spinal Muscular Atrophy Medicine Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Spinal Muscular Atrophy Medicine Production (2021-2032) & (K Dose)
Figure 5. World Spinal Muscular Atrophy Medicine Average Price (2021-2032) & (US$/Dose)
Figure 6. World Spinal Muscular Atrophy Medicine Production Value Market Share by Region (2021-2032)
Figure 7. World Spinal Muscular Atrophy Medicine Production Market Share by Region (2021-2032)
Figure 8. North America Spinal Muscular Atrophy Medicine Production (2021-2032) & (K Dose)
Figure 9. Europe Spinal Muscular Atrophy Medicine Production (2021-2032) & (K Dose)
Figure 10. Asia Spinal Muscular Atrophy Medicine Production (2021-2032) & (K Dose)
Figure 11. Latin America Spinal Muscular Atrophy Medicine Production (2021-2032) & (K Dose)
Figure 12. Middle East Spinal Muscular Atrophy Medicine Production (2021-2032) & (K Dose)
Figure 13. Spinal Muscular Atrophy Medicine Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Spinal Muscular Atrophy Medicine Consumption (2021-2032) & (K Dose)
Figure 16. World Spinal Muscular Atrophy Medicine Consumption Market Share by Region (2021-2032)
Figure 17. United States Spinal Muscular Atrophy Medicine Consumption (2021-2032) & (K Dose)
Figure 18. China Spinal Muscular Atrophy Medicine Consumption (2021-2032) & (K Dose)
Figure 19. Europe Spinal Muscular Atrophy Medicine Consumption (2021-2032) & (K Dose)
Figure 20. Japan Spinal Muscular Atrophy Medicine Consumption (2021-2032) & (K Dose)
Figure 21. South Korea Spinal Muscular Atrophy Medicine Consumption (2021-2032) & (K Dose)
Figure 22. ASEAN Spinal Muscular Atrophy Medicine Consumption (2021-2032) & (K Dose)
Figure 23. India Spinal Muscular Atrophy Medicine Consumption (2021-2032) & (K Dose)
Figure 24. Producer Shipments of Spinal Muscular Atrophy Medicine by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Spinal Muscular Atrophy Medicine Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Spinal Muscular Atrophy Medicine Markets in 2025
Figure 27. United States VS China: Spinal Muscular Atrophy Medicine Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Spinal Muscular Atrophy Medicine Production Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States VS China: Spinal Muscular Atrophy Medicine Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 30. United States Based Manufacturers Spinal Muscular Atrophy Medicine Production Market Share 2025
Figure 31. China Based Manufacturers Spinal Muscular Atrophy Medicine Production Market Share 2025
Figure 32. Rest of World Based Manufacturers Spinal Muscular Atrophy Medicine Production Market Share 2025
Figure 33. World Spinal Muscular Atrophy Medicine Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 34. World Spinal Muscular Atrophy Medicine Production Value Market Share by Type in 2025
Figure 35. Gene Replacement Drug
Figure 36. Antisense Oligonucleotide Drug
Figure 37. Small Molecule Splicing Modifier Drug
Figure 38. Muscle Targeted Drug
Figure 39. World Spinal Muscular Atrophy Medicine Production Market Share by Type (2021-2032)
Figure 40. World Spinal Muscular Atrophy Medicine Production Value Market Share by Type (2021-2032)
Figure 41. World Spinal Muscular Atrophy Medicine Average Price by Type (2021-2032) & (US$/Dose)
Figure 42. World Spinal Muscular Atrophy Medicine Production Value by Administration Method, (USD Million), 2021 & 2025 & 2032
Figure 43. World Spinal Muscular Atrophy Medicine Production Value Market Share by Administration Method in 2025
Figure 44. Intrathecal Injection Drug
Figure 45. Intravenous Infusion Drug
Figure 46. Oral Drug
Figure 47. World Spinal Muscular Atrophy Medicine Production Market Share by Administration Method (2021-2032)
Figure 48. World Spinal Muscular Atrophy Medicine Production Value Market Share by Administration Method (2021-2032)
Figure 49. World Spinal Muscular Atrophy Medicine Average Price by Administration Method (2021-2032) & (US$/Dose)
Figure 50. World Spinal Muscular Atrophy Medicine Production Value by Delivery Vehicle, (USD Million), 2021 & 2025 & 2032
Figure 51. World Spinal Muscular Atrophy Medicine Production Value Market Share by Delivery Vehicle in 2025
Figure 52. Vector Based Drug
Figure 53. Non Vector Drug
Figure 54. World Spinal Muscular Atrophy Medicine Production Market Share by Delivery Vehicle (2021-2032)
Figure 55. World Spinal Muscular Atrophy Medicine Production Value Market Share by Delivery Vehicle (2021-2032)
Figure 56. World Spinal Muscular Atrophy Medicine Average Price by Delivery Vehicle (2021-2032) & (US$/Dose)
Figure 57. World Spinal Muscular Atrophy Medicine Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 58. World Spinal Muscular Atrophy Medicine Production Value Market Share by Application in 2025
Figure 59. Hospital
Figure 60. Pharmacy
Figure 61. Others
Figure 62. World Spinal Muscular Atrophy Medicine Production Market Share by Application (2021-2032)
Figure 63. World Spinal Muscular Atrophy Medicine Production Value Market Share by Application (2021-2032)
Figure 64. World Spinal Muscular Atrophy Medicine Average Price by Application (2021-2032) & (US$/Dose)
Figure 65. Spinal Muscular Atrophy Medicine Industry Chain
Figure 66. Spinal Muscular Atrophy Medicine Procurement Model
Figure 67. Spinal Muscular Atrophy Medicine Sales Model
Figure 68. Spinal Muscular Atrophy Medicine Sales Channels, Direct Sales, and Distribution
Figure 69. Methodology
Figure 70. Research Process and Data Source
